LivaNova (NASDAQ:LIVN) Issues FY 2025 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY 2025 earnings guidance on Tuesday. The company provided EPS guidance of 3.650-3.750 for the period, compared to the consensus EPS estimate of 3.630. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion. LivaNova also updated its FY25 guidance to $3.65-3.75 EPS.

Wall Street Analyst Weigh In

A number of analysts have recently commented on LIVN shares. Mizuho cut their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 14th. Needham & Company LLC reissued a “buy” rating and set a $75.00 target price on shares of LivaNova in a report on Tuesday, January 28th. Finally, Robert W. Baird lifted their price target on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $69.17.

LivaNova Price Performance

Shares of LIVN stock traded down $8.08 during trading hours on Tuesday, reaching $41.42. The company had a trading volume of 622,591 shares, compared to its average volume of 472,555. LivaNova has a 12-month low of $41.42 and a 12-month high of $64.47. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of 99.00 and a beta of 1.00. The stock has a fifty day moving average of $47.94 and a 200-day moving average of $49.64.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.27% of the stock is owned by company insiders.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.